Sunday, biological products maker AstraZeneca plc (AZN: News ,AZN.L: News ) revealed results from a new sub- analysis of the JUPITER, a long-term, randomized, double-blind, placebo-controlled, large-scale study of 17,802 patients. The study was designed to determine if rosuvastatin 20 mg decreases the risk of heart attack, stroke and other major cardiovascular events in patients with low to normal LDL-C but at increased cardiovascular risk as identified by age and elevated high-sensitivity C-reactive protein. The new data were presented at the 58th Annual American College of Cardiology Scientific Sessions in Orlando, Florida.
According to the London, United Kingdom-based drug company, results from a new sub- analysis of the JUPITER study show that patients with low to normal cholesterol levels and elevated high sensitivity C-reactive protein who attained a dual treatment target of LDL-C <70mg/dL and hsCRP <2mg/L with CRESTOR or rosuvastatin calcium 20mg achieved a greater reduction in cardiovascular events compared to placebo than those who did not.
Additional results from this analysis showed patients who achieved an LDL-C <70 mg/dL experienced a 55% reduction in cardiovascular events compared to placebo and that the patients who achieved a dual treatment target of LDL-C<70 mg/dL and hsCRP <1 mg/L achieved a 79% reduction in CV events compared to placebo. Rosuvastatin 20mg was well tolerated in nearly 9,000 patients during the course of the JUPITER study, the company said.
No comments:
Post a Comment